EF
ABBV icon

Elite Financial’s AbbVie ABBV Stock Holding History

Elite Financial’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
1,153
-300
-21% -$64.5K 0.12% 49
2026
Q1 		$316K Sell
1,453
-100
-6% -$22.2K 0.14% 44
2025
Q4 		$354K Hold
1,553
– – 0.16% 43
2025
Q3 		$339K Sell
1,553
-1,128
-42% -$230K 0.16% 43
2025
Q2 		$528K Sell
2,681
-225
-8% -$41.8K 0.26% 36
2025
Q1 		$608K Sell
2,906
-651
-18% -$127K 0.32% 31
2024
Q4 		$632K Buy
+3,557
New +$654K 0.34% 30

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Elite Financial's ABBV Position: Q2 2026 in Review

Elite Financial reduced its AbbVie (ABBV) stake by 21% in Q2 2026, selling an estimated $64.5K and leaving 1,153 shares worth $290K. The position accounts for 0.12% of the portfolio, ranked #49.

Elite Financial first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $632K in Q4 2024. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Elite Financial held 1,153 shares of AbbVie worth $290K as of Q2 2026.
  • Elite Financial sold 300 AbbVie shares in Q2 2026, an estimated $64.5K.
  • AbbVie made up 0.12% of Elite Financial's portfolio in Q2 2026, its #49 holding.
  • Elite Financial first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Elite Financial's AbbVie position peaked at $632K in Q4 2024.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elite Financial's 13F filing for Q2 2026, filed 13 Aug 2026.